BRIEF-GSK and Genmab Get EU Approval for Arzerra

July 3 Thu Jul 3, 2014 10:00am EDT

Related Topics

July 3 (Reuters) - Gsk And Genmab Receive EU Authorisation For Arzerra (Ofatumumab) As First Line treatment for chronic lymphocytic leukaemia (cll) in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based_therapy Source text for Eikon: Further company coverage: [GSK.L GEN.CO ]